enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Olopatadine - Wikipedia

   en.wikipedia.org/wiki/Olopatadine

   A package of generic formulation of olopatadine eye drops sold under the brand name Pallada. Brand names include Pallada, Pazeo, Pataday, Patanol S, Patanol, Opatanol, Olopat, Patanase. [18] [19] It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by Kyowa Hakko Kogyo. [20]

3. Olopatadine/mometasone - Wikipedia

   en.wikipedia.org/wiki/Olopatadine/mometasone

   "Olopatadine".Drug Information Portal.U.S. National Library of Medicine. "Mometasone furoate".Drug Information Portal.U.S. National Library of Medicine.

4. Generic drug - Wikipedia

   en.wikipedia.org/wiki/Generic_drug

   Two women, each claiming to have suffered severe medical complications from a generic version of metoclopramide, lost their Supreme Court appeal on June 23, 2011. In a 5–4 ruling in PLIVA, Inc. v. Mensing , [ 70 ] [ 71 ] the court held that generic companies cannot be held liable for information, or the lack of information, on the originator ...

5. Abbreviated New Drug Application - Wikipedia

   en.wikipedia.org/wiki/Abbreviated_New_Drug...

   The generic version must deliver the same amount of active ingredients into a patient's bloodstream in the same amount of time as the innovator drug. In cases of topically active drugs, the bioequivalence of a drug can be demonstrated by comparing drugs dissolution or transdermal drug absorption is compared with the innovator drug.

6. FDA approves generic versions of ADHD drug Vyvanse - AOL

   www.aol.com/lifestyle/fda-approves-generic...

   The Food and Drug Administration (FDA) approved the first generic versions of Vyvanse, a drug used to treat attention deficit/hyperactivity disorder (ADHD), a decision that comes amid a nationwide ...

7. Drug Price Competition and Patent Term Restoration Act

   en.wikipedia.org/wiki/Drug_Price_Competition_and...

   Drug innovators were given protections in two ways. First, a new kind of market exclusivity was introduced, by means of a new five-year period of data exclusivity awarded when the FDA approves marketing of a drug that is a new chemical entity; during that period the FDA cannot approve a generic version of the drug. [3]